Pavel Viktorovich Markov
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Pavel Viktorovich Markov has a total of 91 co-authors. Here are the top co-authors by number of shared publications:
- Vladimir Yuryevich Struchkov
A.V. Vishnevsky National Medical Research Center of Surgery
12 shared publications - Aleksander Aleksandrovich Goev
National Medical Research Center of Surgery named after A. Vishnevsky
7 shared publications - AleksandrAleksandr I. Burmistrov
A.V. Vishnevsky National Medical Research Center of Surgery
7 shared publications - Evgeniy Alexandrovich Akhtanin
National Medical Research Center of Surgery named after A. Vishnevsky
7 shared publications - Mikhail Vyacheslavovich Dvukhzhilov
A.V. Vishnevsky National Medical Research Center of Surgery
7 shared publications - Ovanes Robertovich Arutyunov
A.V. Vishnevsky National Medical Research Center of Surgery
7 shared publications
Latest Publications
- Open Access
- 5 October 2026
- Published by Annals of Surgical Hepatology in Annaly khirurgicheskoy gepatologii = Annals of HPB surgery
- Vol. 31 (3) , 82-89
Diagnosis and treatment of patients with solid pseudopapillary neoplasms
Aim. To present our experience in treating patients with solid pseudopapillary tumors of the pancreas from 2007 to 2024. Material and methods. Data from 66 patients with confirmed solid pseudopapillary neoplasms were analyzed. Results. Symptoms were observed in 35 patients (53 %). According to CT and MRI findings, the preoperative diagnosis was unambiguous in 38 patients (57.5 %). All patients underwent surgery. Distal pancreatectomy was performed in 38 patients (57.6 %), pancreatoduodenectomy in 11 patients (16.7 %), enucleation in 13 patients (19.7 %), and medial resection in four patients (6.1 %). Open surgeries occurred in 36 cases (54.5 %), while laparoscopic and robotic surgeries occurred in 30 cases (45.4 %). Complications developed in 23 patients (34.8 %); one patient died (1.5 %). Histological examination revealed a pseudocapsule in 64.4 % of cases, parenchymal invasion in 25.4 %, and peripancreatic tissue invasion in 23.7 %. Lymphovascular invasion was present in 5.1 % of cases. There was no perineural invasion or lymph node metastasis. One patient was found to have liver metastases during diagnosis. Long-term outcomes were monitored in 57 patients (89 %); the mean follow-up period was 74.8 months (6–207 months). Only the patient with metastases experienced disease progression and died after 36 months. The five- and ten-year overall survival rates were 93.3 %. The five-year recurrence-free survival rate was 96.6 %, and the ten-year recurrence-free survival rate was 92.9 %. Conclusion. Solid pseudopapillary neoplasms of the pancreas are rare conditions that are becoming more frequently diagnosed. Timely surgical treatment yields favorable short- and long-term outcomes.
- 5 October 2026
- Published by Annals of Surgical Hepatology in Annaly khirurgicheskoy gepatologii = Annals of HPB surgery
- Vol. 31 (3) , 82-89
Open AccessDiagnosis and treatment of patients with solid pseudopapillary neoplasms
Aim. To present our experience in treating patients with solid pseudopapillary tumors of the pancreas from 2007 to 2024. Material and methods. Data from 66 patients with confirmed solid pseudopapillary neoplasms were analyzed. Results. Symptoms were observed in 35 patients (53 %). According to CT and MRI findings, the preoperative diagnosis was unambiguous in 38 patients (57.5 %). All patients underwent surgery. Distal pancreatectomy was performed in 38 patients (57.6 %), pancreatoduodenectomy in 11 patients (16.7 %), enucleation in 13 patients (19.7 %), and medial resection in four patients (6.1 %). Open surgeries occurred in 36 cases (54.5 %), while laparoscopic and robotic surgeries occurred in 30 cases (45.4 %). Complications developed in 23 patients (34.8 %); one patient died (1.5 %). Histological examination revealed a pseudocapsule in 64.4 % of cases, parenchymal invasion in 25.4 %, and peripancreatic tissue invasion in 23.7 %. Lymphovascular invasion was present in 5.1 % of cases. There was no perineural invasion or lymph node metastasis. One patient was found to have liver metastases during diagnosis. Long-term outcomes were monitored in 57 patients (89 %); the mean follow-up period was 74.8 months (6–207 months). Only the patient with metastases experienced disease progression and died after 36 months. The five- and ten-year overall survival rates were 93.3 %. The five-year recurrence-free survival rate was 96.6 %, and the ten-year recurrence-free survival rate was 92.9 %. Conclusion. Solid pseudopapillary neoplasms of the pancreas are rare conditions that are becoming more frequently diagnosed. Timely surgical treatment yields favorable short- and long-term outcomes.
- 27 January 2026
- Published by Media Sphere Publishing Group in Pirogov Russian Journal of Surgery
- No. 1,p. 6-13
Bile duct injuries following cholecystectomy: current situation in the Russian Federation
Objective. To assess the current situation regarding iatrogenic bile duct injuries (BDI) in the Russian Federation. Material and methods. A retrospective analysis enrolled cases of BDI that required reconstructive surgery in 2023. Data were collected through online survey of medical institutions registered in annual reporting database of the Chief Surgeon of the Russian Ministry of Health, where BDIs were documented. Results. There were 227 BDIs. Data from 126 (59.0%) patients were obtained via online survey. Laparoscopic cholecystectomy (LC) was performed in 107 (84.9%) cases. Acute cholecystitis was indication in 77 (61.1%) cases. BDI occurred in 25 (19.8%) cases at the first level hospitals, 69 (54.8%) cases — at the second level, 32 (25.4%) cases — at the third level facilities. Intraoperative diagnosis of BDI was established in 62 (49.2%) cases. According to the Strasberg classification, type D injuries accounted for 32 cases, type E — 94 cases. Roux-en-Y hepaticojejunostomy was performed in 72 (57.1%) cases, bilio-biliary anastomosis over a T-tube — 20 (15.9%), bile duct repair over a stent — 8 (6.3%), primary bile duct suture without stent — 9 (7.1%), hemihepatectomy — 1 (0.8%), external biliary drainage — 12 (9.5%), other procedures — 4 (3.2%). Surgical approach and outcomes depended on timing of BDI diagnosis and type of intervention. Complications were observed in 20 (15.9%) cases, including hepaticojejunal anastomotic failure in 10/72 patients (13.9%). Overall mortality rate was 4.8%. The reported leading cause of BDI (83.3% of respondents) was difficult bile duct identification due to fibrotic-inflammatory changes in subhepatic space. Conclusion. The main cause of BDI during cholecystectomy is fibrotic-inflammatory changes in subhepatic space. Compliance with principles of safe cholecystectomy is of paramount importance. BDI requires referral to a specialized center. Timely diagnosis of BDI improves the outcomes.
- 27 January 2026
- Published by Media Sphere Publishing Group in Pirogov Russian Journal of Surgery
- No. 1,p. 6-13
Bile duct injuries following cholecystectomy: current situation in the Russian Federation
Objective. To assess the current situation regarding iatrogenic bile duct injuries (BDI) in the Russian Federation. Material and methods. A retrospective analysis enrolled cases of BDI that required reconstructive surgery in 2023. Data were collected through online survey of medical institutions registered in annual reporting database of the Chief Surgeon of the Russian Ministry of Health, where BDIs were documented. Results. There were 227 BDIs. Data from 126 (59.0%) patients were obtained via online survey. Laparoscopic cholecystectomy (LC) was performed in 107 (84.9%) cases. Acute cholecystitis was indication in 77 (61.1%) cases. BDI occurred in 25 (19.8%) cases at the first level hospitals, 69 (54.8%) cases — at the second level, 32 (25.4%) cases — at the third level facilities. Intraoperative diagnosis of BDI was established in 62 (49.2%) cases. According to the Strasberg classification, type D injuries accounted for 32 cases, type E — 94 cases. Roux-en-Y hepaticojejunostomy was performed in 72 (57.1%) cases, bilio-biliary anastomosis over a T-tube — 20 (15.9%), bile duct repair over a stent — 8 (6.3%), primary bile duct suture without stent — 9 (7.1%), hemihepatectomy — 1 (0.8%), external biliary drainage — 12 (9.5%), other procedures — 4 (3.2%). Surgical approach and outcomes depended on timing of BDI diagnosis and type of intervention. Complications were observed in 20 (15.9%) cases, including hepaticojejunal anastomotic failure in 10/72 patients (13.9%). Overall mortality rate was 4.8%. The reported leading cause of BDI (83.3% of respondents) was difficult bile duct identification due to fibrotic-inflammatory changes in subhepatic space. Conclusion. The main cause of BDI during cholecystectomy is fibrotic-inflammatory changes in subhepatic space. Compliance with principles of safe cholecystectomy is of paramount importance. BDI requires referral to a specialized center. Timely diagnosis of BDI improves the outcomes.
- Open Access
- 5 January 2026
- Published by ECO-Vector LLC (Publications) in Journal of Clinical Practice
- Vol. 16 (4) , 63-76
Radical surgery following inadequate drainage procedures for cystic neoplasms of the pancreas
BACKGROUND: Despite the presence of national and international recommendations on the diagnostics and treatment of cystic lesions in the pancreas, the consequences of inappropriate drainage procedures for pancreatic cystic neoplasms mistaken for the post-necrotic pancreatic pseudocysts, remain only fragmentally researched and are mainly presented by single observations or small case series without the detailed analysis of the delay of the radical intervention and of the effects of previous surgeries on the complexity and on the immediate results of resection. Reminding about this problem based on the analysis of our own clinical experience is important for the prevention of such tactical mistakes. AIM: The analysis of the remote results and of the consequences of non-radical draining surgeries conducted in patients with pancreatic cystic neoplasms, initially mistakenly diagnosed as benign pancreatic cysts. METHODS: From January 2016 until February 2025, out of the 177 patients with previous resection interventions in the pancreas due to having the cystic lesions, a group of 19 (10.7%) patients was isolated, which previously underwent the non-radical draining surgeries. A retrospective analysis was arranged on the data of their treatment and the postoperative complications, as well as the comparison of preoperative diagnoses to the data from the definitive histological examination. RESULTS: All the 19 patients with a past draining intervention had a reported recurrence of the cystic lesion within the period from 2 weeks to 84 months (with the median of 6 months). During the repeated pre-operative examination, the following conditions were diagnosed: mucinous cystic neoplasm (15; 78.9%), main-duct intraductal papillary mucinous neoplasm (2; 10.5%), solid pseudopapillary neoplasm (1; 5.3%), and suspected adenocarcinoma (1; 5.3%). All the patients underwent the radical resections: the pancreaticoduodenectomy (in 4) and the distal pancreatectomy (in 15). The complications of grade III and higher acc. to the classification by Clavien–Dindo were developing in 5 (26.3%) patients, there were no deaths. The definitive histological diagnosis has confirmed the preoperative conclusion on the mucinous cystic neoplasm in 86.7% of the cases (13/15); other cases were the verified serous cystadenoma and the solid pseudopapillary neoplasm. The diagnoses of the solid pseudopapillary neoplasm and the adenocarcinoma, set before surgery, were completely matching to the morphological data. CONCLUSION: The patients with cystic lesions in the pancreas must receive the comprehensive examination at the pre-operative stage for the precise differential diagnostics of the post-necrotic cysts and the cystic tumor. The inappropriate drainage procedures in cases of cystic tumor in the pancreas does not lead to recovery, it delays the radical surgery, which can complicate its further course and worsen the treatment prognosis.
- 5 January 2026
- Published by ECO-Vector LLC (Publications) in Journal of Clinical Practice
- Vol. 16 (4) , 63-76
Open AccessRadical surgery following inadequate drainage procedures for cystic neoplasms of the pancreas
BACKGROUND: Despite the presence of national and international recommendations on the diagnostics and treatment of cystic lesions in the pancreas, the consequences of inappropriate drainage procedures for pancreatic cystic neoplasms mistaken for the post-necrotic pancreatic pseudocysts, remain only fragmentally researched and are mainly presented by single observations or small case series without the detailed analysis of the delay of the radical intervention and of the effects of previous surgeries on the complexity and on the immediate results of resection. Reminding about this problem based on the analysis of our own clinical experience is important for the prevention of such tactical mistakes. AIM: The analysis of the remote results and of the consequences of non-radical draining surgeries conducted in patients with pancreatic cystic neoplasms, initially mistakenly diagnosed as benign pancreatic cysts. METHODS: From January 2016 until February 2025, out of the 177 patients with previous resection interventions in the pancreas due to having the cystic lesions, a group of 19 (10.7%) patients was isolated, which previously underwent the non-radical draining surgeries. A retrospective analysis was arranged on the data of their treatment and the postoperative complications, as well as the comparison of preoperative diagnoses to the data from the definitive histological examination. RESULTS: All the 19 patients with a past draining intervention had a reported recurrence of the cystic lesion within the period from 2 weeks to 84 months (with the median of 6 months). During the repeated pre-operative examination, the following conditions were diagnosed: mucinous cystic neoplasm (15; 78.9%), main-duct intraductal papillary mucinous neoplasm (2; 10.5%), solid pseudopapillary neoplasm (1; 5.3%), and suspected adenocarcinoma (1; 5.3%). All the patients underwent the radical resections: the pancreaticoduodenectomy (in 4) and the distal pancreatectomy (in 15). The complications of grade III and higher acc. to the classification by Clavien–Dindo were developing in 5 (26.3%) patients, there were no deaths. The definitive histological diagnosis has confirmed the preoperative conclusion on the mucinous cystic neoplasm in 86.7% of the cases (13/15); other cases were the verified serous cystadenoma and the solid pseudopapillary neoplasm. The diagnoses of the solid pseudopapillary neoplasm and the adenocarcinoma, set before surgery, were completely matching to the morphological data. CONCLUSION: The patients with cystic lesions in the pancreas must receive the comprehensive examination at the pre-operative stage for the precise differential diagnostics of the post-necrotic cysts and the cystic tumor. The inappropriate drainage procedures in cases of cystic tumor in the pancreas does not lead to recovery, it delays the radical surgery, which can complicate its further course and worsen the treatment prognosis.
- 29 December 2025
- Published by Kuban State Medical University in Kuban Scientific Medical Bulletin
- Vol. 32 (6)
Postoperative pancreatitis as a specific complication after pancreatoduodenectomy: A single-center retrospective cohort study
Background. Post-pancreatectomy acute pancreatitis is a serious, procedure-specific complication that occurs after pancreatoduodenectomy. However, only in 2022 did the International Study Group of Pancreatic Surgery formulate a clear definition and diagnostic criteria for post-pancreatectomy pancreatitis. Objective. To determine the incidence of post-pancreatectomy acute pancreatitis according to the current ISGPS definition and classification, to assess risk factors for this complication, and to evaluate its association with other procedure-specific postoperative complications following pancreatoduodenectomy. Methods. A single-center retrospective cohort study was conducted based on review of medical record of 451 patients who underwent pancreatic resections at the Department of Abdominal Surgery of the National Medical Research Center of Surgery named after A.V. Vishnevsky between January 2021 and May 2025. A total of 147 patients who underwent pancreatoduodenectomy were included in the analysis. All patients were divided into two groups: those who developed post-pancreatectomy acute pancreatitis (per ISGPS criteria) and those without this complication. Primary endpoints included: incidence and severity score of post-pancreatectomy acute pancreatitis; its impact on overall postoperative morbidity; overall frequency of procedure-specific postoperative complications and each complication separately (pancreatic fistula, postoperative hemorrhage, delayed gastric emptying); frequency of reoperations; postoperative length of stay; length of stay in the intensive care unit; and in-hospital mortality. Potential risk factors for post-pancreatectomy acute pancreatitis were assessed. Results. Persistent elevation of serum amylase for at least the first two postoperative days occurred in 29/147 patients (19.7%). According to ISGPS criteria, 7/147 patients (4.8%) were classified as having postoperative hyperamylasemia rather than a complication. Post-pancreatectomy acute pancreatitis developed in 22/147 patients (14.9%): grade B in 14 cases (9.5%) and grade C in 8 cases (5.4%). Post-pancreatectomy acute pancreatitis had a significant impact on postoperative course. These patients had a significantly longer postoperative hospital stay (p < 0.001), longer ICU stay (p < 0.001), a higher overall rate of postoperative complications (p < 0.001), and a higher rate of severe complications (Clavien–Dindo ≥ 3) (p = 0.002), including procedure-specific complications (p < 0.001). Clinically relevant pancreatic fistulas (p < 0.001), postoperative hemorrhage (p = 0.003), and delayed gastric emptying (p = 0.016) occurred more frequently; reoperations were more common (p = 0.001); and mortality was significantly higher (18.2% vs. 3.2%; p = 0.018). Comparative analysis showed that post-pancreatectomy acute pancreatitis developed significantly more often in patients with diagnoses other than pancreatic ductal adenocarcinoma or chronic pancreatitis (p = 0.011), in those with a “soft” pancreatic texture (p = 0.008), a narrow main pancreatic duct (p = 0.007), and with a high abundance of acinar structures in the pancreatic section (p = 0.001). Multivariate analysis demonstrated statistical significance only for the high proportion of acinar structures in the pancreatic specimen and intraoperative blood loss. Conclusion. Post-pancreatectomy acute pancreatitis now has a well-established definition and clear diagnostic criteria, including severity score. It substantially affects the postoperative course, often necessitating additional conservative or interventional treatment and, at times, reoperation. Accounting for risk factors for post-pancreatectomy acute pancreatitis may help improve short-term outcomes following pancreatoduodenectomy.
- 29 December 2025
- Published by Kuban State Medical University in Kuban Scientific Medical Bulletin
- Vol. 32 (6)
Postoperative pancreatitis as a specific complication after pancreatoduodenectomy: A single-center retrospective cohort study
Background. Post-pancreatectomy acute pancreatitis is a serious, procedure-specific complication that occurs after pancreatoduodenectomy. However, only in 2022 did the International Study Group of Pancreatic Surgery formulate a clear definition and diagnostic criteria for post-pancreatectomy pancreatitis. Objective. To determine the incidence of post-pancreatectomy acute pancreatitis according to the current ISGPS definition and classification, to assess risk factors for this complication, and to evaluate its association with other procedure-specific postoperative complications following pancreatoduodenectomy. Methods. A single-center retrospective cohort study was conducted based on review of medical record of 451 patients who underwent pancreatic resections at the Department of Abdominal Surgery of the National Medical Research Center of Surgery named after A.V. Vishnevsky between January 2021 and May 2025. A total of 147 patients who underwent pancreatoduodenectomy were included in the analysis. All patients were divided into two groups: those who developed post-pancreatectomy acute pancreatitis (per ISGPS criteria) and those without this complication. Primary endpoints included: incidence and severity score of post-pancreatectomy acute pancreatitis; its impact on overall postoperative morbidity; overall frequency of procedure-specific postoperative complications and each complication separately (pancreatic fistula, postoperative hemorrhage, delayed gastric emptying); frequency of reoperations; postoperative length of stay; length of stay in the intensive care unit; and in-hospital mortality. Potential risk factors for post-pancreatectomy acute pancreatitis were assessed. Results. Persistent elevation of serum amylase for at least the first two postoperative days occurred in 29/147 patients (19.7%). According to ISGPS criteria, 7/147 patients (4.8%) were classified as having postoperative hyperamylasemia rather than a complication. Post-pancreatectomy acute pancreatitis developed in 22/147 patients (14.9%): grade B in 14 cases (9.5%) and grade C in 8 cases (5.4%). Post-pancreatectomy acute pancreatitis had a significant impact on postoperative course. These patients had a significantly longer postoperative hospital stay (p < 0.001), longer ICU stay (p < 0.001), a higher overall rate of postoperative complications (p < 0.001), and a higher rate of severe complications (Clavien–Dindo ≥ 3) (p = 0.002), including procedure-specific complications (p < 0.001). Clinically relevant pancreatic fistulas (p < 0.001), postoperative hemorrhage (p = 0.003), and delayed gastric emptying (p = 0.016) occurred more frequently; reoperations were more common (p = 0.001); and mortality was significantly higher (18.2% vs. 3.2%; p = 0.018). Comparative analysis showed that post-pancreatectomy acute pancreatitis developed significantly more often in patients with diagnoses other than pancreatic ductal adenocarcinoma or chronic pancreatitis (p = 0.011), in those with a “soft” pancreatic texture (p = 0.008), a narrow main pancreatic duct (p = 0.007), and with a high abundance of acinar structures in the pancreatic section (p = 0.001). Multivariate analysis demonstrated statistical significance only for the high proportion of acinar structures in the pancreatic specimen and intraoperative blood loss. Conclusion. Post-pancreatectomy acute pancreatitis now has a well-established definition and clear diagnostic criteria, including severity score. It substantially affects the postoperative course, often necessitating additional conservative or interventional treatment and, at times, reoperation. Accounting for risk factors for post-pancreatectomy acute pancreatitis may help improve short-term outcomes following pancreatoduodenectomy.
- 26 December 2025
- Published by VSMU N.N. Burdenko in Journal of Experimental and Clinical Surgery
- Vol. 18 (4) , 291-303
Current approach to nutritional support in patients with enterocutaneous fistulas
Enterocutaneous fistulas (ECFs) are a severe and potentially life-threatening complication that occurs primarily after abdominal surgery or inflammatory diseases of the gastrointestinal tract, such as Crohn's disease, diverticulitis and complicated forms of ulcerative colitis. ECF is accompanied by pronounced disorders of the water-electrolyte and protein-energy balance, the development of infectious complications, sepsis, as well as severe nutritional insufficiency. The latter is one of the key factors determining the prognosis in this category of patients, significantly affecting the outcome of treatment, the duration of hospitalization, terms of the fistula healing and the mortality rate. This review examines in detail modern approaches to nutritional support for patients with ECF at various stages of treatment. The article highlights the diagnosis options for nutritional deficiency, including clinical and laboratory parameters, scales for assessing nutritional status and instrumental control options. Special attention is paid to the indications for parenteral, enteral and combined nutrition, the choice of route and composition of nutritional mixtures, as well as the potential use of special substrates (glutamine, omega-3 fatty acids, etc.) to modulate the metabolic response and reduce inflammation. The data from leading clinical studies on the effectiveness of various nutritional support strategies in patients with enterocutaneous fistulas, including those in specialized centers, are analyzed. The review provides an overview of current recommendations from international expert communities, including ESPEN, ASPEN, the experience of Chinese colleagues and Russian experts. The need for an individualized approach to the choice of nutritional tactics is emphasized, taking into account the localization, the volume of intestinal discharge losses, the general condition of a patient and the phase of the disease.
- 26 December 2025
- Published by VSMU N.N. Burdenko in Journal of Experimental and Clinical Surgery
- Vol. 18 (4) , 291-303
Current approach to nutritional support in patients with enterocutaneous fistulas
Enterocutaneous fistulas (ECFs) are a severe and potentially life-threatening complication that occurs primarily after abdominal surgery or inflammatory diseases of the gastrointestinal tract, such as Crohn's disease, diverticulitis and complicated forms of ulcerative colitis. ECF is accompanied by pronounced disorders of the water-electrolyte and protein-energy balance, the development of infectious complications, sepsis, as well as severe nutritional insufficiency. The latter is one of the key factors determining the prognosis in this category of patients, significantly affecting the outcome of treatment, the duration of hospitalization, terms of the fistula healing and the mortality rate. This review examines in detail modern approaches to nutritional support for patients with ECF at various stages of treatment. The article highlights the diagnosis options for nutritional deficiency, including clinical and laboratory parameters, scales for assessing nutritional status and instrumental control options. Special attention is paid to the indications for parenteral, enteral and combined nutrition, the choice of route and composition of nutritional mixtures, as well as the potential use of special substrates (glutamine, omega-3 fatty acids, etc.) to modulate the metabolic response and reduce inflammation. The data from leading clinical studies on the effectiveness of various nutritional support strategies in patients with enterocutaneous fistulas, including those in specialized centers, are analyzed. The review provides an overview of current recommendations from international expert communities, including ESPEN, ASPEN, the experience of Chinese colleagues and Russian experts. The need for an individualized approach to the choice of nutritional tactics is emphasized, taking into account the localization, the volume of intestinal discharge losses, the general condition of a patient and the phase of the disease.
- Open Access
- 28 November 2025
- Published by Vidar, Ltd. in Medical Visualization
- Vol. 29 (4) , 81-93
Assessment of machine learning in radiomics for predicting the risk of clinically significant pancreatic fistulas after pancreatoduodenal resections using CT imaging
Despite the reduction in mortality after pancreatoduodenal resections, the incidence of postoperative complications remains high (20–60%). One of the most severe complications is postoperative pancreatic fistula. Predicting the risks of a complicated postoperative period remains an urgent problem. One of the key risk factors is the pancreatic structure, and modern approaches to predicting clinically relevant pancreatic fistula integrate not only morphological but also radiomic parameters of CT images using artificial intelligence methods. Aim. To evaluate the potential of machine learning in radiomics for predicting clinically relevant pancreatic fistulas after pancreatoduodenal resection and to develop a clinical decision support system based on the “Virtual Biopsy” platform. Methods. Retrospective analysis of data from 117 patients who underwent pancreatoduodenal resection (2016–2019) at the A.V. Vishnevsky National Medical Research Center of Surgery. Machine learning methods were applied to assess textural features of preoperative CT scans. Results. Сlinically relevant pancreatic fistulas were recorded in 31 patients (26.5%). Clinically significant fistula alone was diagnosed in 11 patients (9.4%), while its combination with arrosive bleeding was observed in 20 patients (17.1%). The peak incidence of fistulas occurred on days 4–6, and of bleeding on days 8–14. The radiomic AdaBoost model demonstrated the highest efficacy (ROC AUC = 0.815), outperforming alternative approaches: Gradient Boosting (0.631), XGBoost (0.677), LightGBM (0.631), and Stacking (0.662). Integration of morphological features did not improve predictive capability, likely due to data noise. Models based on semantic parameters (max. ROC AUC = 0.653) confirmed limited clinical applicability. Conclusion. Machine learning methods are effective in predicting clinically relevant pancreatic fistulas after pancreatoduodenal resections. Radiomic analysis extends the diagnostic potential of CT, demonstrating superior model accuracy metrics compared to classical semantic features alone.
- 28 November 2025
- Published by Vidar, Ltd. in Medical Visualization
- Vol. 29 (4) , 81-93
Open AccessAssessment of machine learning in radiomics for predicting the risk of clinically significant pancreatic fistulas after pancreatoduodenal resections using CT imaging
Despite the reduction in mortality after pancreatoduodenal resections, the incidence of postoperative complications remains high (20–60%). One of the most severe complications is postoperative pancreatic fistula. Predicting the risks of a complicated postoperative period remains an urgent problem. One of the key risk factors is the pancreatic structure, and modern approaches to predicting clinically relevant pancreatic fistula integrate not only morphological but also radiomic parameters of CT images using artificial intelligence methods. Aim. To evaluate the potential of machine learning in radiomics for predicting clinically relevant pancreatic fistulas after pancreatoduodenal resection and to develop a clinical decision support system based on the “Virtual Biopsy” platform. Methods. Retrospective analysis of data from 117 patients who underwent pancreatoduodenal resection (2016–2019) at the A.V. Vishnevsky National Medical Research Center of Surgery. Machine learning methods were applied to assess textural features of preoperative CT scans. Results. Сlinically relevant pancreatic fistulas were recorded in 31 patients (26.5%). Clinically significant fistula alone was diagnosed in 11 patients (9.4%), while its combination with arrosive bleeding was observed in 20 patients (17.1%). The peak incidence of fistulas occurred on days 4–6, and of bleeding on days 8–14. The radiomic AdaBoost model demonstrated the highest efficacy (ROC AUC = 0.815), outperforming alternative approaches: Gradient Boosting (0.631), XGBoost (0.677), LightGBM (0.631), and Stacking (0.662). Integration of morphological features did not improve predictive capability, likely due to data noise. Models based on semantic parameters (max. ROC AUC = 0.653) confirmed limited clinical applicability. Conclusion. Machine learning methods are effective in predicting clinically relevant pancreatic fistulas after pancreatoduodenal resections. Radiomic analysis extends the diagnostic potential of CT, demonstrating superior model accuracy metrics compared to classical semantic features alone.
- 20 October 2025
- Published by PANORAMA Publishing House in Hirurg (Surgeon)
- No. 5,p. 61-71
Nutritional support at the stages of surgical treatment of patients with intestinal fistulas
The review analyzes the data of modern domestic and foreign literature on the issues of nutritional support for patients with intestinal fistulas. Intestinal fistula is a serious and frequent complication of both planned and emergency surgical interventions on the abdominal organs. An unformed small intestinal fistula has no prospects for radical surgical treatment. Correction of nutritional deficiency in patients with «large» losses is crucial for preparing for radical surgical treatment. The aim. To present modern methods for correcting nutritional deficiencies in patients with intestinal fistulas and their possible complications. Materials and methods. The analysis of publications devoted to nutritional support at the stages of treatment of patients with COP using the databases eLibrary, CyberLeninka, PubMed, Web of Science and Google Scholar from 1970 to 2023 was carried out. A total of 2,413 sources were found, and further analysis included 46 publications directly related to the research topic.
- 20 October 2025
- Published by PANORAMA Publishing House in Hirurg (Surgeon)
- No. 5,p. 61-71
Nutritional support at the stages of surgical treatment of patients with intestinal fistulas
The review analyzes the data of modern domestic and foreign literature on the issues of nutritional support for patients with intestinal fistulas. Intestinal fistula is a serious and frequent complication of both planned and emergency surgical interventions on the abdominal organs. An unformed small intestinal fistula has no prospects for radical surgical treatment. Correction of nutritional deficiency in patients with «large» losses is crucial for preparing for radical surgical treatment. The aim. To present modern methods for correcting nutritional deficiencies in patients with intestinal fistulas and their possible complications. Materials and methods. The analysis of publications devoted to nutritional support at the stages of treatment of patients with COP using the databases eLibrary, CyberLeninka, PubMed, Web of Science and Google Scholar from 1970 to 2023 was carried out. A total of 2,413 sources were found, and further analysis included 46 publications directly related to the research topic.
- Open Access
- 26 September 2025
- Published by VSMU N.N. Burdenko in Journal of Experimental and Clinical Surgery
- Vol. 18 (3) , 195-207
Combined pancreatic solid-pseudo-papillary tumor and spleen lesions: diagnosis complexities in determining treatment tactics
Solid pseudopapillary tumors (SPTs) are rare neoplasms, which account for less than 2% of exocrine pancreatic tumors. These are low-grade epithelial malignancies. Currently, there are no data on SPT metastasis to the spleen in the literature. However, due to the rare SPT incidence and the ongoing accumulation and data analysis on these type of tumors globally, the presence of a combined cystic-solid structure lesion in the spleen does not allow us to exclude such a situation. Two clinical cases of SPT combined with focal spleen lesions are presented. The first one is with a cystic lesion verified as cavernous spleen lymphangioma according to the morphology of the removed lesion. Despite the fact that the splenic lesions included in the differential series during examination were benign, the size of the lesion and the risk of its rupture demonstrated the advisability of spleen resection performing. The second one is combined with multiple spleen hemangiomas verified by preoperative MSCT, which allowed performing a sparing operation - median resection (tumor enucleation) of the pancreatic head. Thus, а thorough examination of patients with combined focal lesions, one of which being SPT, a tumor with malignant potential, allows us to clearly determine the entire volume of the lesion and determine the correct surgical tactics.
- 26 September 2025
- Published by VSMU N.N. Burdenko in Journal of Experimental and Clinical Surgery
- Vol. 18 (3) , 195-207
Open AccessCombined pancreatic solid-pseudo-papillary tumor and spleen lesions: diagnosis complexities in determining treatment tactics
Solid pseudopapillary tumors (SPTs) are rare neoplasms, which account for less than 2% of exocrine pancreatic tumors. These are low-grade epithelial malignancies. Currently, there are no data on SPT metastasis to the spleen in the literature. However, due to the rare SPT incidence and the ongoing accumulation and data analysis on these type of tumors globally, the presence of a combined cystic-solid structure lesion in the spleen does not allow us to exclude such a situation. Two clinical cases of SPT combined with focal spleen lesions are presented. The first one is with a cystic lesion verified as cavernous spleen lymphangioma according to the morphology of the removed lesion. Despite the fact that the splenic lesions included in the differential series during examination were benign, the size of the lesion and the risk of its rupture demonstrated the advisability of spleen resection performing. The second one is combined with multiple spleen hemangiomas verified by preoperative MSCT, which allowed performing a sparing operation - median resection (tumor enucleation) of the pancreatic head. Thus, а thorough examination of patients with combined focal lesions, one of which being SPT, a tumor with malignant potential, allows us to clearly determine the entire volume of the lesion and determine the correct surgical tactics.
- Open Access
- 22 September 2025
- Published by Annals of Surgical Hepatology in Annaly khirurgicheskoy gepatologii = Annals of HPB surgery
- Vol. 30 (3) , 80-89
Enucleation and resections short-term operative outcomes for well-differentiated pancreatic neuroendocrine tumors
Aim. To evaluate the short-term outcomes of enucleation and resection procedures for G1 and G2 pancreatic neuroendocrine tumors (PNETs).Materials and Methods. The study included 171 patients diagnosed with G1 and G2 pancreatic neuroendocrine tumors. Pancreatoduodenectomy was performed in 25 patients, distal pancreatic resection in 60, and tumor enucleation in 86 cases.Results. Neuroendocrine tumors in the head and neck of the pancreas were identified in 79 patients. Enucleation was performed in 54 cases, and pancreatoduodenectomy in 25. Postoperative complications following enucleation occurred in 22 patients (40.7%), with 1 death; complications after pancreatoduodenectomy were observed in 9 patients (36%), also with 1 death. Tumors located in the body and tail were diagnosed in 92 patients. Enucleation was performed in 32 cases, and distal pancreatic resection in 60. Postoperative complications occurred in 5 patients (15.6%) after enucleation and in 27 patients (45.5%) after distal pancreatic resection.Conclusion. For well-differentiated pancreatic neuroendocrine tumors, enucleation is a feasible surgical option. The choice of surgical procedure depends on tumor size, its anatomic location with respect to the main pancreatic duct, and the surgeon’s clinical judgment.
- 22 September 2025
- Published by Annals of Surgical Hepatology in Annaly khirurgicheskoy gepatologii = Annals of HPB surgery
- Vol. 30 (3) , 80-89
Open AccessEnucleation and resections short-term operative outcomes for well-differentiated pancreatic neuroendocrine tumors
Aim. To evaluate the short-term outcomes of enucleation and resection procedures for G1 and G2 pancreatic neuroendocrine tumors (PNETs).Materials and Methods. The study included 171 patients diagnosed with G1 and G2 pancreatic neuroendocrine tumors. Pancreatoduodenectomy was performed in 25 patients, distal pancreatic resection in 60, and tumor enucleation in 86 cases.Results. Neuroendocrine tumors in the head and neck of the pancreas were identified in 79 patients. Enucleation was performed in 54 cases, and pancreatoduodenectomy in 25. Postoperative complications following enucleation occurred in 22 patients (40.7%), with 1 death; complications after pancreatoduodenectomy were observed in 9 patients (36%), also with 1 death. Tumors located in the body and tail were diagnosed in 92 patients. Enucleation was performed in 32 cases, and distal pancreatic resection in 60. Postoperative complications occurred in 5 patients (15.6%) after enucleation and in 27 patients (45.5%) after distal pancreatic resection.Conclusion. For well-differentiated pancreatic neuroendocrine tumors, enucleation is a feasible surgical option. The choice of surgical procedure depends on tumor size, its anatomic location with respect to the main pancreatic duct, and the surgeon’s clinical judgment.
- Open Access
- 30 July 2025
- Published by Remedium, Ltd. in Meditsinskiy sovet = Medical Council
- No. 10,p. 56-64
Clinical case of therapy for BRCA1-associated metastatic pancreatic cancer
The article presents a clinical case of a patient with BRCA1-associated metastatic pancreatic cancer (mPC) who received first-line chemotherapy with mFOLFIRINOX followed by a transition to maintenance therapy with olaparib (300 mg 2 times a day). During the treatment, significant regression of the tumor and liver metastases, normalization of the CA-19-9 level (from 952 to 7 U/ml) were achieved. The patient underwent conditional radical surgery to remove the primary tumor, and olaparib therapy was continued. The clinical case illustrates the effectiveness of targeted therapy with PARP inhibitors in patients with BRCA1/2 mutations and emphasizes the importance of genetic testing in PCa and gives reason to think about the place of PARP inhibitors in adjuvant therapy. Nowadays olaparib is the standard of care for patients with gBRCA-mutated (including BRCA1) mPCa who have achieved disease control on first-line platinum-based chemotherapy. Long-term results are encouraging, demonstrating the potential for long-term disease control in a significant proportion of patients. Data on response to therapy and survival indicate a significant discrepancy in the effectiveness of treatment for patients with or without mutations. Thus, the median overall survival (OS) in BRCA-positive mPC without therapy is 8–12 months (which is comparable to sporadic mPC), and with chemotherapy (FOLFIRINOX/gemcitabine + cisplatin) it reaches 18–22 months. Maintenance therapy with olaparib after treatment with platinum drugs increases progression-free survival (PFS): 7.4 months versus 3.8 months without therapy. This indicates the high significance of BRCA1/2 testing in PC. The issue of surgical treatment of patients with mPCa who have responded positively to therapy remains highly controversial and requires further study. There is insufficient data on the adjuvant (after radical surgery) therapy regimen, but studies are underway (APOLLO, NCT04858334).
- 30 July 2025
- Published by Remedium, Ltd. in Meditsinskiy sovet = Medical Council
- No. 10,p. 56-64
Open AccessClinical case of therapy for BRCA1-associated metastatic pancreatic cancer
The article presents a clinical case of a patient with BRCA1-associated metastatic pancreatic cancer (mPC) who received first-line chemotherapy with mFOLFIRINOX followed by a transition to maintenance therapy with olaparib (300 mg 2 times a day). During the treatment, significant regression of the tumor and liver metastases, normalization of the CA-19-9 level (from 952 to 7 U/ml) were achieved. The patient underwent conditional radical surgery to remove the primary tumor, and olaparib therapy was continued. The clinical case illustrates the effectiveness of targeted therapy with PARP inhibitors in patients with BRCA1/2 mutations and emphasizes the importance of genetic testing in PCa and gives reason to think about the place of PARP inhibitors in adjuvant therapy. Nowadays olaparib is the standard of care for patients with gBRCA-mutated (including BRCA1) mPCa who have achieved disease control on first-line platinum-based chemotherapy. Long-term results are encouraging, demonstrating the potential for long-term disease control in a significant proportion of patients. Data on response to therapy and survival indicate a significant discrepancy in the effectiveness of treatment for patients with or without mutations. Thus, the median overall survival (OS) in BRCA-positive mPC without therapy is 8–12 months (which is comparable to sporadic mPC), and with chemotherapy (FOLFIRINOX/gemcitabine + cisplatin) it reaches 18–22 months. Maintenance therapy with olaparib after treatment with platinum drugs increases progression-free survival (PFS): 7.4 months versus 3.8 months without therapy. This indicates the high significance of BRCA1/2 testing in PC. The issue of surgical treatment of patients with mPCa who have responded positively to therapy remains highly controversial and requires further study. There is insufficient data on the adjuvant (after radical surgery) therapy regimen, but studies are underway (APOLLO, NCT04858334).